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Background: Chongkukjang is a traditional Korean fermented product prepared from soybeans and re-
ported to have multiple biological functions, including antidiabetic, antiinﬂammatory, and neuro-
protective effects. Inﬂuenza is a respiratory disease caused by inﬂuenza viruses and continues to be a
worldwide threat with a high potential to cause pandemics. Besides vaccination, only two classes of
drugs are available for antiviral treatment against these pathogens.
Methods: We tested the inhibitory activity of an ethyl acetate extract from Chongkukjang toward
inﬂuenza A virus neuraminidase.
Results: All 10 compounds extracted from Chongkukjang showed neuraminidase inhibitory activity.
Extracts A3 and A8, with high neuraminidase content, had the best inhibitory activities. The in vivo
antiinﬂuenza virus activities of the ethyl acetate, A3, and A8 extracts as well as commercially available
genistein were evaluated using H1N1 (A/NWS/33) to test mice survivability after virus challenge. The
Chongkukjang extracts did not reduce mortality, but the A3 and A8 extracts delayed the median time to
death after inﬂuenza A virus infection of mice.
Conclusion: Our results suggest that the Chongkukjang extracts may have potential as a therapeutic
agent to treat inﬂuenza virus infection.
Copyright © 2015, Korea Food Research Institute, Published by Elsevier. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chongkukjang is a fermented product manufactured by short-
term fermentation of soybean using Bacillus subtilis that contains
many microorganisms and bioactive compounds that are absent
from unfermented soybeans (Fig. 1) [1e3]. Flavonoid glycosides are
converted into aglycones by hydrolysis during fermentation of
Chongkukjang, and many of the proteins are degraded into small
peptides and amino acids [4]. Koreans have been consuming
Chongkukjang for hundreds of years, and most believe that
Chongkukjang consists of proteins and minerals that promote the




titute, Published by Elsevier. This issystem [5,6]. Chongkukjang has multiple functions, including
antidiabetic, antiinﬂammatory, and neuroprotective effects [5,7].
Inﬂuenza viruses are respiratory pathogens that affect humans
and are responsible for substantial morbidity, mortality, and
decreased productivity worldwide [8]. Inﬂuenza viruses contain
two glycoproteins on their surface, hemagglutinin (HA) and neur-
aminidase (NA), which recognize sialic acid in hostecell glyco-
conjugates. HA binds to terminal sialic acid groups on cell surface
glycoconjugates, leading to attachment and subsequent penetra-
tion of virus into cells, and NA exhibits enzymatic activity that
removes sialic acid from glycoconjugates, facilitating the release of
progeny virions from infected cells and preventing the aggregation
of progeny virions [9]. Neuraminidase inhibitors (NAIs) act by
binding to the active site of the viral NA enzyme and preventing
release and spread of progeny virions from infected cells during the
replication cycle [10]. NAIs block the neuraminidase active site and
prevent release and spread of new virions [11]. NA was chosen as a
suitable drug target because it plays a major role in the propagation
of inﬂuenza viruses, and the amino acid residues of the active sitean open access article under the CC BY-NC-ND license (http://creativecommons.org/
Fig. 1. Chongkukjang is a traditional Korean fermented product prepared from soy-
bean. Chongkukjang is manufactured via the short-term fermentation of soybeans
using Bacillus subtilis.
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active site of the enzyme are strictly conserved [12]. Treating
inﬂuenza with NAIs has become the most popular treatment
among primary care doctors. NAIs were introduced to clinical
practice in 1999, but so far only zanamivir and oseltamivir have
been licensed for use in humans [13]. Unfortunately, viruses
resistant to zanamivir and oseltamivir have been generated in vitro
and in humans recently [14]. This highlights the urgent need for
newand readily available antiinﬂuenza agents. In the present study,
we investigated the antiinﬂuenza activities of Chongkukjang ex-
tracts and demonstrated their efﬁcacy.2. Materials and methods
2.1. Viruses
The inﬂuenza virus used in this study (Inﬂuenza A/NWS/33;
Inﬂuenza A/chicken/Korea/MS96/96) was propagated in the allan-
toic sac of 10-day-old speciﬁc pathogen-free embryonated eggs.
These virus stocks were frozen at 80C until use. Viral HA units
were determined in 96-well microtiter plates using 1% chicken red
blood cells.2.2. Fluorometric neuraminidase activity assay
A ﬂuorescence-based NA inhibition assaywas used to determine
the sensitivity of the viruses to NAIs. The assay is based on the
release of a 4-methylumbelliferone ﬂuorescent product from the 2-
(4-methylumbelliferyl)-a-d-N-acetylneuraminic acid (MUNANA)
substrate (Sigma, St. Louis, MO, USA) as a measure of NA activity.
The NA activity assay was carried out to determine the dilution of
each virus to be used in the subsequent NA inhibition assay. Two-
fold dilutions of virus in assay buffer (32.5mM MES [2-(N-mor-
pholino)ethanesulfonic acid], pH 6.5, 4mM CaCl2 with 0.1% NP-40,
and 0.3 mg/mL bovine serum albumin) were prepared, mixed
with an equal volume (50 mL) of MUNANA substrate (0.3mM), and
incubated at 37C for 60 minutes. The reaction was terminated by
adding 100 mL stop solution (0.14M NaOH in 83% ethanol). The
ﬂuorometric quantiﬁcation of 4-methylumbelliferone wasdetermined using a VICTOR X4 Multilabel Plate Reader (Perki-
nElmer Inc., Waltham, MA, USA) at an excitation wavelength of
360 nm and an emission wavelength of 448 nm. The appropriate
concentration of virus for use in the NA inhibition assay was
determined by selecting a dilution of virus in the linear portion of
the enzyme activity curve. Zanamivir was obtained from Sigma and
used as a positive control.
This assay was performed in duplicate for each isolate, and the
half-maximal inhibitory concentration (IC50) value for each virus
and for each antiviral agent was determined. The IC50 is the anti-
viral agent concentration that inhibits 50% of neuraminidase
activity.
2.3. Isolation of an active component from Chongkukjang
Commercial Chongkukjang samples were obtained from Sun-
chang MoonOkrae Food (Sunchang, Korea), and the extracts were
prepared by the Korea Food Research Institute. Brieﬂy, Chongkuk-
jang was extracted with ethanol, and the liquid was removed by
evaporation. The residue was suspended and successively parti-
tioned in fractions of ethyl acetate, butanol, and water. The total
crude extract was dissolved in CH2Cl2/H2O (95:5), and the ethyl
acetate fraction was subjected to silica open-column chromatog-
raphy. The mobile phase solvent was dichloromethane/ethanol
diluted as 95:5, 90:10, 80:20, and 50:50. All 10 subfractions were
combined (A1eA10) based on thin-layer chromatography analysis.
2.4. Animal model and experimental design
Female (weight, 17e19 g) 6-week-old speciﬁc pathogen-free
BALB/c mice (Daejeon, Chungnam, Korea) were used. The mice
were quarantined 24 hours prior to use. The AIN-93M diet was
provided as feed throughout the experiment, as recommended by
the American Institute of Nutrition [15]. All animals received hu-
mane care in compliance with the National Association of Labora-
tory Animal Care and were fed in isolation (Three-Shine, Daejeon,
Korea).
To investigate the safety of the Chongkukjang extract in mice,
the mice were administered the ethyl acetate, A3, and A8 fractions,
as well as genistein (0.4 g/kg/d of body weight). Phosphate-
buffered saline was given to the normal control group. The mice
were divided into groups of 10 each, and the treatments were
carried out for 14 days. Clinical signs were recorded daily, and the
body weight was measured on Days 0, 7, 10, and 14.
To investigate the protective activity of the Chongkukjang ex-
tracts against lethal inﬂuenza virus in vivo, the mice were divided
into groups of 10 each. The inoculated mice received the ethyl ac-
etate, A3, and A8 extracts as well as genistein (0.2 and 0.4 g/kg/d),
respectively. The treatments were administered daily via gavages
for 6 days before challenge and 14 days after inﬂuenza A virus
challenge. Studies with mice were performed as described previ-
ously, and phosphate-buffered saline was used as the negative
control. The mice were anesthetized with diethyl ether and
exposed to 0.1 mL virus by intranasal instillation. A viral challenge
dose of 107.0 50% embryo infectious dose (EID50)/0.1 mL (A/NWS/
33), which was approximately 80e90% of the lethal dose, was used.
Mice were observed daily for 14 days after infection. The protective
effect was estimated by preventing death and prolonging the me-
dian time to death (MTD).
2.5. Data analysis
Data are expressed as the mean ± standard deviation of at least
three independent experiments. Body weight was analyzed with
one-way analysis of variance [16]. Statistical analyses were
Table 2
Body weights (mean ± standard deviation) of the mice in each group.*
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value <0.05 was considered statistically signiﬁcant.Group Body weight (g)
0 DPI 7 DPI 10 DPI 14 DPI
Negative 18.6 ± 0.5 18.6 ± 0.8 19.2 ± 0.8 19.7 ± 0.5
Ethyl acetate extract (0.4 g/kg) 17.9 ± 0.5 19.4 ± 0.6 20.3 ± 1.1 20.3 ± 1.2
A3 (0.4 g/kg) 18.0 ± 0.3 19.5 ± 1.0 20.4 ± 1.6 20.7 ± 1.9
A8 (0.4 g/kg) 18.1 ± 0.7 18.7 ± 0.5 19.2 ± 0.8 19.7 ± 0.4
Genistein (0.4 g/kg) 17.9 ± 0.4 18.7 ± 0.8 19.4 ± 1.4 20.5 ± 1.1
DPI, days post inoculation.
* Safety of the Chongkukjang extract in mice administered with ethyl acetate, A3,
and A8 fractions, as well as genistein (0.4 g/kg/d of body weight) for consecutive 14
days.3. Results
3.1. Inhibitory effect of the Chongkukjang extracts on inﬂuenza
virus in vitro
The standard soybean isoﬂavones, such as daidzin, daidzein,
genistin, genistein, glycitin, and glycitein (Sigma), were applied to
the ﬂuorometric NA activity assay, and genistein showed the best
NA inhibitory effect compared with that of the ﬁve other standard
soybean isoﬂavones (data not shown). Thus, genistein was used to
control the extract composition of the Chongkukjang eluent at each
step.
NA is one of the most important targets to screen antiinﬂuenza
virus A drugs. We ﬁrst investigated whether the Chongkukjang
fractions exerted antiviral action. The ethyl acetate, butanol, and
water fractions were measured using the ﬂuorometric NA activity
assay. The ethyl acetate fraction showed the best NA inhibitory
effect compared with that of butanol and water (data not shown).
Thus, the ethyl acetate fraction was used for further puriﬁcation.
The Chongkukjang extracts were dose-dependently effective
against inﬂuenza A virus, and the calculated IC50 values of the ex-
tracts against the inﬂuenza virus are shown in Table 1. The A3
extract showed the best NA inhibitory effect against inﬂuenza A
virus. The A8 extract also showed a high inhibitory effect. The
Chongkukjang extract seemed to be more effective against A/NWS/
33 (H1N1) than against A/chicken/Korea/MS96/9 (H9N2). Genistein
showed similar effects against A/NWS/33 (H1N1) and A/chicken/
Korea/MS96/96 (H9N2).3.2. Inhibitory effect of the Chongkukjang extracts on the inﬂuenza
virus in vivo
We next tested whether the Chongkukjang extract, which
inhibited NA activity, could relieve a viral infection in vivo. First, we
assessed the safety of the Chongkukjang extract in mice. Animals
treated with the Chongkukjang extract maintained a relatively
steady weight, and mean body weights of the treated mice, except
the A8 group, were higher than those of the control group, but no
signiﬁcant differences were observed throughout the study
(Table 2). No clinical symptoms were observed throughout the
study.
To investigate the protective effect of the Chongkukjang extract
in vivo, groups of mice were inoculated with 107.0 EID50/0.1 mL A/
NWS/33 (H1N1). All of the mice that received the ethyl acetate, A3,
and A8 extracts as well as genistein (0.4 g/kg/d) died within the
experimental period (data not shown). The results for mice that
received a dose of 0.2 g/kg/d are shown in Fig. 2. About 10% of theTable 1
Inhibitory effect of the Chongkukjang extracts against inﬂuenza A virus.*





8,482.5 ± 124.3 14,264.2.5 ± 1,183.1
2 A3 17,611.1 ± 3,052.7 28,242.4 ± 2,571.5
3 A8 4,565.9 ± 66.9 8,949.3 ± 974.3
4 Genistein 30,58.8 ± 218.9 2,729.6 ± 275.1
IC50, drug concentration required to inhibit half of neuraminidase activity.
* Fluorescence-based neuraminidase (NA) inhibition assay was used to determine
the sensitivity of inﬂuenza A viruses to Chongkukjang extracts.mice from the positive control group survived until the end of the
experiment. All challenge groups, except the genistein group (0.2 g/
kg) and the A3 group (0.2 g/kg), died by 8 days after infection. The
MTD of the mice treated with the A3 and A8 (0.2 g/kg) extracts was
5 and 6 days, which was longer than that of the viral control group
(3 days). The survival rate in the A3 group (0.2 g/kg) at 14 days post
infection was 20%, which was higher than that of the viral control
group (10%).4. Discussion
There is an urgent medical need to develop new strategies
against inﬂuenza virus infection. At the moment antiviral drugs are
the only known defense against the disease, as no vaccine is
available, which is similar to the early phase of a pandemic or when
the prediction for the seasonal inﬂuenza vaccine composition fails.
In 2010, theWorld Health Organization suggested the development
of novel and effective treatment strategies for inﬂuenza virus
including natural products [17]. This prompted us to investigate the
antiviral activity of traditional food extracts against inﬂuenza virus
infection. The goal of this study was to determine whether
Chongkukjang extracts could function as an antiviral agent against
inﬂuenza A virus, because Chongkukjang has a strong record in the
literature for its beneﬁcial effects on human health [12,18]. Our
results suggest for the ﬁrst time that the Chongkukjang extracts
were active against the inﬂuenza A virus.
Inﬂuenza virus NA is thought to be required to secrete newly
synthesized virus from infected cells and to aid in the movement of
the virus. NA can be administered relatively late in the viral infec-
tion and still render a signiﬁcant antiviral effect [19]. Genistein
showed a better effect than the A3 and A8 extracts against A/NWS/
33 (H1N1) and A/chicken/Korea/MS96/96 (H9N2), suggesting that
other active compounds may be present within this extract. This
result agreed with those for the ethyl acetate fraction, which
showed less efﬁciency than the further puriﬁed A3 and A8 extracts.
Although the Chongkukjang extracts showed less activity than
zanamivir and oseltamivir, Chongkukjang extracts showed possible
research directions as a potential candidate for zanamivir- and
oseltamivir-resistant cases in clinical practice. This provides a good
backdrop considering that after 3 years of NAI use, it has been noted
that 0.35% of isolates were found to have become resistantdin
particular, higher percentages of such resistance have been
observed in children [20,21].
Wide variations in the IC50 for oseltamivir are observed in sea-
sonal inﬂuenza A with or without the virus subtype [22]. Genistein
has a weak NA inhibitory effect of about 20 mg/mL IC50 against the
H1N1 inﬂuenza A virus [23]. Our result showed about six times
higher efﬁciency of the IC50 against the same NA type of inﬂuenza A
virus. An NA gene mutation (H274Y, H275Y in N1 numbering) has
been associated with NA inhibitor susceptibility [24]. The
Fig. 2. The in vivo protective activities of the Chongkukjang extracts on lethal inﬂuenza A virus-infected mice. The treatments were administered daily via gavages for 6 days before
challenge and 14 days after inﬂuenza A virus challenge. Cumulative survival curve for the indicated groups (n ¼ 10/group).
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NWS/33 (H1N1) than that against A/chicken/Korea/MS96/96
(H9N2). This result agrees with the ﬁnding that avian isolates have
signiﬁcantly higher resistance to NAIs than that of human isolates
[25]. It is not apparent how accurately the IC50 values determined
from the enzyme inhibition assay results reﬂect actual differences
in inhibitor potency. Once efﬁcacy is observed against an inﬂuenza
virus, it is important to use a variety of other virus strains in follow-
up evaluations to ascertain if the antiviral effect applies to all viral
strains encountered in the clinic.
As the Chongkukjang extracts showed antiviral effects in vitro, a
mouse study was performed to determine the in vivo effects of the
Chongkukjang extracts against inﬂuenza A virus. Treatment with
the A3 and A8 (0.2 g/kg) extracts produced a modest inhibitory
effect on inﬂuenza A virus replication in mice. Inﬂuenza virus-
infected mice receiving the Chongkukjang extract treatment did
not show reduced mortality, but the A3 and A8 extracts delayed
the mice MTD after inﬂuenza A virus infection. This result shows
that the Chongkukjang extract is a potential candidate to ﬁght
inﬂuenza A virus infection. The Chongkukjang-treated groups
(except the A8 group) maintained a higher body weight compared
with the control group, which agrees with previous reports that
soybean-related products increase body weight and lower the risk
of toxic side effects at a low concentration [14,26]. This extract may
be a potent antiviral agent against inﬂuenza virus with no host
toxicity.
We found that the A3 and A8 Chongkukjang extracts had a
potential inhibitory activity against inﬂuenza viruses. This study is
another example showing how plant extracts are capable of
inhibiting inﬂuenza A virus infection. This study addresses the
latest developments in theoretical and experimental research on
the properties of NA that are and will be driving antiinﬂuenza drug
development today and in the near future. Two further research
directions can be undertaken. One would be to further characterize
and identify the antiviral compounds in the extracts. Nevertheless,
it is also important to determine whether only one compound,
several closely related compounds, or the composite activity of
several different molecules is/are responsible for the observed
antiviral activity and whether the activity is selective for inﬂuenza
viruses. We clearly need to focus more attention on ethnic foods,
not only for nutrition but also for the functionality they provide in
disease control.Conﬂicts of interest
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